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Abstract
Background: Biologic’ therapies, such as autologous conditioned serum (ACS), are gaining popularity in treating
orthopaedic conditions in equine veterinary medicine. Evidence is scarce regarding ACS constituents, and large
inter-individual differences in cytokine and growth factor content have been demonstrated. The objective of the
current study was to investigate the potential association between cytokine and growth factor content of ACS and
clinical effect in harness racehorses with spontaneously occurring low-grade articular lameness. Horses received 3
intra-articular injections of ACS administered at approximately 2-week intervals. Lameness evaluation consisting of a
trot-up with subsequent flexions tests was performed at inclusion and approximately 2 weeks after the last
treatment (re-evaluation); horses were classified as responders when there was no detectable lameness on trot-up
and a minimum of 50% reduction in flexion test scores at re-evaluation. Association between clinical outcome
(responders vs. non-responders) and age, lameness grades at inclusion (both initial trot-up and after flexion tests),
treatment interval, follow-up time and the ACS content of IL-1Ra, IGF-1 and TGF-β was determined by regression
modelling.
Results: Outcome analysis was available for 19 of 20 included horses; 11 responded to treatment whereas 8 did
not. There was considerable inter-individual variability in cytokine/growth factor content of ACS, and in the majority
of the horses, the level of IL-10, IL-1β and TNF-α was below the detection limit. In the final multivariate logistic
regression model, ACS content of IGF-1 and IL-1Ra was significantly associated with clinical response (P = 0.01 and
P = 0.03, respectively). No association with clinical response was found for the other tested variables.
Conclusions: The therapeutic benefit of ACS may be related to higher levels of IL-1Ra and IGF-1. Our study corroborates
previous findings of considerable inter-individual variability of cytokine- and growth factor content in ACS.
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Background
Since the report of its effectiveness in improving lameness
in horses with experimentally induced carpal osteoarthritis
(OA), intra-articular treatment with autologous condi-
tioned serum (ACS) is becoming increasingly more popu-
lar in equine practice [1, 2]. ACS is a biologic blood
product obtained by aseptic incubation of the patient’s
blood in the presence of monocyte-activating surfaces,
followed by centrifugation and subsequent extraction of
the serum fraction [3, 4]. Compared to un-manipulated
blood, ACS contains increased amounts of anti-
inflammatory cytokines and growth factors such as
interleukin 1 receptor antagonist (IL-1Ra), interleukin 10
(IL-10), transforming growth factor β (TGF-β), insulin-
like growth factor 1 (IGF-1) and platelet-derived growth
factor (PDGF) [3–7]. Although the exact composition of
ACS is unknown, the proposed disease-modifying mech-
anism in joint disease is believed to be due to IL-1Ra
blocking the IL-1 receptor, thereby preventing detrimental
effects of IL-1β on articular tissues in OA pathophysiology
[3, 8, 9]. However, for effective receptor blockade to occur,
IL-1Ra has to significantly out-number IL-1β; in human
chondrocytes, the required ratio for 50% inhibition of IL-1
activity has been reported as approximately 100:1 [10]. In
horses, the optimal therapeutic IL-1Ra:IL-1β ratio has not
been determined [11].
Considerable inter-individual differences in ACS con-
stituents have been reported by several research groups [4,
12, 13], and current literature has failed to identify a prep-
aration method where such variability is limited or negli-
gible [4, 7, 12, 13]. Although patient-related factors such
as inflammatory status have been shown to influence ACS
cytokine profile [12], predictors for cytokine and growth
factor production in ACS have yet to be identified. Conse-
quently, if the therapeutic effect of ACS is determined by
the levels of the anti-inflammatory constituents known to
date, using ACS in equine clinical practice could be con-
sidered a hit-and-miss approach, as there is no method of
identifying animals with sub-therapeutic ACS cytokine
levels. On the other hand, short clearance time of ACS cy-
tokines in vivo supports the counter argument that cyto-
kine profile of ACS is of little therapeutic significance [6].
Therefore, as a first step in investigating a potential link
between cytokine profile and therapeutic efficacy of ACS,
the objective of the current study was to evaluate clinical
response to ACS in horses with spontaneously occurring
low-grade articular lameness, and to investigate the poten-
tial association between cytokine and growth factor con-
tent of ACS and treatment response. Based on previous
clinical experience, we hypothesized that treated horses
would fall into one of two outcome categories (responders
and non-responders), and that these categories would be
associated with the cytokine and growth factor profile of
the ACS.
Results
Case details and clinical examination
Included horses comprised 12 Norwegian-Swedish
Coldblooded trotters and 8 Standardbreds; see Table 1
for case details. Subjective and objective lameness
evaluation including diagnostic anaesthesia was per-
formed as described in the methods section. Ten
horses presented with lameness localized to one joint
in one limb; one horse presented with lameness local-
ized to two joints in one limb. Two-limb lameness
was identified in 9 horses; among these, 5 horses pre-
sented with bilateral forelimb lameness in which
lameness of the least lame limb (secondary problem)
could only be detected after successfully alleviating
the lameness of the most lame limb (primary prob-
lem) with diagnostic anaesthesia. Three horses had ip-
silateral fore and hind limb lameness, whereas one
horse presented with diagonal fore and hind limb
lameness (Table 1). In all horses, a primary problem
as defined in the methods section could be identified;
the primary problem affected a forelimb in 14 horses
and a hind limb in 6 horses (Table 1).
When assessing the most lame limb at the initial trot-
up, mean AAEP (American Association of Equine Prac-
titioners) score was 1/5 (median 1/5) and the mean ob-
jective lameness measurements were 16.1 ± 10.8 mm for
forelimbs and 5.9 ± 2.9 mm for hind limbs, respectively.
When assessing the most severe flexion test at inclusion,
mean AAEP score was 2/5 (median 2/5) and the mean
objective lameness measurements were 37.9 ± 15.0 mm
for forelimbs and 18.6 ± 4.1 mm for hind limbs, respect-
ively. Radiographic findings are presented in Table 1.
Treatment and re-evaluation
Horses were treated with 3 ACS injections, mean treat-
ment interval was 14 days (median 15 days). Adverse ef-
fects were noted for one horse (Case 13) in which the
third ACS injection of the medial femorotibial joint re-
sulted in septic arthritis; this horse was subsequently ex-
cluded from re-evaluation and outcome analysis.
For all horses, mean time from inclusion to re-
evaluation was 48 days (median 43 days), and the mean
AAEP score at re-evaluation trot-up was 0.5/5 (median
0/5); the mean objective lameness measurements were
6.9 ± 4.4 mm for forelimbs and 7.8 ± 2.6 mm for hind
limbs, respectively; mean AAEP score after flexion was
0.5/5 (median 1/5), and the mean objective lameness
measurements after flexion were 15.0 ± 7.5 mm for fore-
limbs and 10.5 ± 5.8 mm for hind limbs, respectively. At
re-evaluation, joint effusion was subjectively improved in
8 horses (6 responders and 2 non-responders); un-
changed in 10 (5 responders and 5 non-responders), and
more pronounced in 1 horse (non-responder).
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Outcome analyses
The objective measurements were significantly corre-
lated to the AAEP scores (for forelimb assessments, cor-
relation coefficient was 0.82, P < 0.0001; whereas for
hind limb assessments, correlation coefficient was 0.79,
P = 0.0071); therefore, only the AAEP scores were used
for further analyses. Based on the pre-set criteria defined
in the methods section, 11 horses were classified as re-
sponders to treatment, whereas 8 horses were defined as
non-responders (Fig. 1). When comparing these two
groups, there were no statistically significant differences
in lameness scores at inclusion (mean and median AAEP
trot-up score 1/5 in both groups, respectively, P = 0.51;
mean and median AAEP flexion test score 2/5 in the re-
sponders and 1.5/5 in the non-responders, respectively,
P = 0.52). There were no statistically significant differ-
ences between the outcome groups in age (5.1 ± 1.5 years
in responders, and 4.9 ± 1.5 years in non-responders, re-
spectively, P = 0.77); treatment interval (16.8 ± 4.1 days in
responders and 16.1 ± 3.4 days in non-responders,
respectively, P = 0.56); follow-up time (48 ± 16 days for
responders, and 43 ± 2 days for non-responders respect-
ively, P = 0.4); or ACS volume used (13.1 ± 4ml in re-
sponders and 14.1 ± 2.7 ml in the non-responders,
respectively; P = 0.56).
The ACS content of IL-1Ra, IGF-1 and TGF-β is de-
tailed in Fig. 2. The majority of IL-10, IL-1β and TNF-α
measurements fell below or near the lower limit of de-
tection even at the lowest possible dilution and were
therefore omitted from statistical analyses (data not
shown).
Through univariate logistic regression modelling, a sig-
nificant association between the outcome groups and
the ACS levels of IGF-1 (P = 0.014) and IL-1Ra (P = 0.04)
was identified (Fig. 2). No association between outcome
and lameness scores at inclusion (initial trot-up and
flexion tests, P = 0.66 and P = 0.61, respectively), age
(P = 0.98), treatment interval (P = 0.66), time to follow-
up (P = 0.15); volume of ACS used (P = 0.53) or the ACS
levels of TGF- β (P = 0.63) was found. When including
Table 1 Study population
Case no. Breed Age Sex 1° problem 2° problem Radiographic findings Responder
1 NSCT 5 G R carpus – WNL Y
2 NSCT 2 G L carpus – Palmar deviation of the carpus (calf kneed) N
3 STB 6 F L carpus – Mild heterogenous radiopacity RCB Y
4 NSCT 4 M L TCJ RF MCPJ WNL Y
5 STB 2 F L carpus – Smoothly marginated non-union fracture
proximal MCII
N
6 STB 3 G L MCPJ R MCPJ Mild remodeling dorsoproximal medial P1, L Y
7 NSCT 2 F L carpus – Mild remodeling dorsoproximal RCB Y
8 NSCT 7 F L carpus L MCPJ Mild remodeling dorsodistal medial radius and
dorsoproximal RCB
N
9 NSCT 5 F L TCJ L carpus Mild remodeling dorsodistal RCB N
10 NSCT 3 G L MCPJ R MCPJ Mild remodeling dorsoproximal medial P1, bilateral N
11 NSCT 7 F LF DIPJ R DIPJ WNL Y
12 STB 4 G L MCPJ R MCPJ Mild remodeling dorsoproximal medial P1, bilateral.
Mild remodeling palmarodistal medial PSB, bilateral
Y
13 NSCT 7 G R stifle R MCPJ WNL NA
14 NSCT 5 G R MCPJ R MTPJ WNL Y
15 STB 6 G L MCPJ R MCPJ Mild remodeling dorsoproximal medial P1, bilateral Y
16 NSCT 5 F L TCJ – Mild heterogeneous radiopacity of the medial malleolus
of the tibia
N
17 STB 7 F R MTPJ – WNL N
18 STB 7 G L MCPJ – Mild remodeling dorsoproximal medial P1 with a small
dorsomedial osteochondral fragment
N
19 NSCT 4 G R TCJ – WNL N
20 STB 5 G LF DIPJ – WNL Y
Case details including radiographic findings and treatment outcome (responder Y: yes, N: no, NA: not available) for horses included in the study. NSCT Norwegian-
Swedish Coldblooded Trotter, STB Standardbred, G gelding, F female, M intact male, R right, L left, LF left front, RF right front, TCJ tarsocrural joint, MCPJ
metacarpophalangeal joint, DIPJ distal interphalangeal joint, RCB radiocarpal bone, MCII second metacarpal bone, P1 proximal phalanx, PSB proximal sesamoid
bone, WNL within normal limit.
Marques-Smith et al. BMC Veterinary Research          (2020) 16:181 Page 3 of 9
Fig. 1 Bar graphs (mean ± standard deviation) illustrating lameness grades (AAEP scale; 0–5) at inclusion (trot-up and flexion) and at re-evaluation
(trot-up and flexion) in 19 horses included in the study for which outcome data was available. Re-evaluation grades were used to categorize
horses into responders (grey bars; n = 11) and non-responders (red bars, n = 8) to treatment. There was no statistical difference in inclusion grades
between the outcome groups
Fig. 2 Box-and-whisker plots illustrating ACS content (ng/ml) of IL-1Ra (dark grey boxes), IGF-1 (light grey boxes) and TGF-β (white boxes) in
horses categorized as responders (n = 11) versus non-responders (n = 8) to ACS treatment. Asterisks indicate significant differences between
outcome groups (P < 0.05)
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ACS levels of IGF-1 and IL-1Ra in the multivariate re-
gression model, both factors were significantly associated
with outcome (P = 0.01 and P = 0.04, respectively), with
higher levels found in horses that responded to treat-
ment (Fig. 2).
Discussion
Results from the current study demonstrate that 58% of
included horses responded to ACS treatment, and that
these horses had higher ACS levels of IL-1Ra and IGF-1
than non-responders. The other investigated ACS con-
stituents were either not found statistically different
(TGF-β) or were at too low levels to be assessed (IL-1β,
IL-10 and TNF-α). To the authors’ knowledge, this is
the first study relating ACS content of IL-1Ra and IGF-1
to treatment outcome in spontaneously occurring low
grade equine articular lameness.
Albeit small, the treatment effect reported in the
current study is corroborated by clinical studies in
human patients with knee OA [14, 15] as well as in
an experimental model of induced equine carpal OA
[1]. However, when evaluating the effect of ACS
in vitro, only minimal beneficial effects on equine
chondrocyte metabolism were found [16]. Discrepan-
cies in reported ACS effects should be interpreted in
the light of the different models used, where in vitro
models might be too simplistic for replicating the
complex pathophysiology taking place in a diseased
synovial joint. On the other hand, the smaller clinical
response observed in our study compared to the ex-
perimental study by Frisbie et al. [1], could potentially
be due to the heterogenous nature of joint pathology
and disease duration characterizing spontaneous trau-
matic OA [17]. In order to limit this variability, our
study population consisted of horses with low grade
lameness only. However, as clinical signs including
lameness grade and absence of radiographic abnor-
malities may correlate poorly with the severity of the
underlying joint disease [17], the non-responders in
our study might have been affected by more severe
joint disease including subchondral bone pathology,
than the responders. Advanced diagnostics such as
magnetic resonance imaging or computed tomography
could have revealed underlying pathology especially of
the subchondral bone [18] whereas articular cartilage
health could have been evaluated by diagnostic arth-
roscopy. However, the substantial cost and relative in-
vasiveness of such procedures negated their routine
use in the current study.
The association between treatment response and ACS
levels of IL-1Ra and IGF-1 was not surprising, as previ-
ous studies have demonstrated positive effects of both of
these mediators on joint health [9, 19, 20]. The anti-
inflammatory/anti-catabolic effect of IL-1Ra is dose-
dependent, as an excess of IL-1Ra relative to IL-1 is ne-
cessary for functional IL-1 receptor blockade to occur
[21]. The anabolic effects of IGF-1, such as stimulation
of matrix aggrecan and collagen synthesis, are also dose-
dependent [22]. Therefore, the contention that higher
IL-1Ra and IGF-1 ACS levels would positively influence
treatment response, seems logical. In fact, delivering a
combination of these two mediators by gene therapy has
been studied in vitro [23] as well as in vivo [24]. An
additive effect on repair processes in chondrocytes de-
pleted by IL-1β was seen when using IL-1Ra in combin-
ation with IGF-1 versus IGF-1 alone [23]. When treating
experimentally created cartilage defects in equine joints,
the IL-1Ra/IGF-1 combination resulted in improved
quality of the repair tissue compared to placebo [24].
The treatment protocol used in the current study was
based on the commonly used clinical protocol of 3 injec-
tions spaced approximately 2 weeks apart; this protocol
is, however, not founded on scientific evidence but ra-
ther on clinical opinion and experience. Recently, a 2-
day injection interval was found superior to the trad-
itional weekly regime in reducing synovial fluid bio-
markers of joint inflammation in horses diagnosed with
OA over a follow-up period of 42 days; however, clinical
effects were not reported [13]. If clinically effective, this
treatment protocol would be of interest to the equine in-
dustry, as a shorter treatment duration could potentially
lead to fewer days away from training. The long treat-
ment duration was particularly problematic to owners
and trainers of non-responders in the current study and
both from a veterinary as well as an industry perspective,
identifying potential non-responders prior to initiation
of ACS therapy would have been ideal. Previous at-
tempts at predicting ACS profile based on patient factors
such as leukocyte levels have failed [12], most likely due
to the large inter-individual variations in ACS cytokine
levels. In humans, part of this variation is explained by
genetic polymorphism, where monocyte production of
IL-1Ra and IL-1β is dictated by the alleles at the IL-1Ra
gene [25]. While genetic polymorphism at this gene
might be present in horses as well, other factors such as
inflammatory status also influence ACS profile [12].
Thus, if the clinical response associated to ACS content
indicated by our data is corroborated by larger studies,
having a stall-side kit for analysis of ACS constituents
such as IL-1Ra could potentially be used to guide patient
selection for similar treatments in the future.
Adverse effects of treatment with ACS were identified
in one horse in the current study, which developed sep-
tic arthritis of the medial femorotibial joint after receiv-
ing the third ACS injection. This reaction was attributed
to the procedure rather than the ACS itself, as the reac-
tion affected only one of several injected joint compart-
ments. In general, the risk of adverse effects of intra-
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articular ACS treatment is low, and in humans compar-
able to injections of saline [15].
The main limitation of our study was the small sample
size. As such, it is possible that additional associations
between clinical outcome and ACS constituents could
have been detected if investigated in a larger population.
Also, the inclusion of different limbs and joints added to
the clinical heterogeneity of our material, and finally, al-
though we aimed for standardized treatment and re-
evaluation intervals, owner availability and convenience
resulted in some variability for these parameters. Having
the horses stabled at the institution for the duration of
the study would have negated this problem; this was
however cost prohibitive for the current study. However,
no significant differences in treatment interval and time
to re-evaluation were found between groups and neither
were these parameters correlated with response to
treatment.
During study planning, inclusion of a control group
was considered. However, due to the studied popula-
tion being client-owned horses and the negative im-
pact such design would have on the client’s
willingness to participate and remain in the study,
this alternative was not considered feasible. Also, the
rationale for treating all joints identified as a source
of pain was based on ethical considerations (i.e
refraining from treating a diagnosed joint problem),
as well as uncertainty regarding client compliance
where any perceived delay in treatment and return to
training would strongly discourage study participation.
The decision to restrict analysis of treatment response
to the primary problem also has some limitations.
While not ideal (optimally, a more homogenous
population with a single affected joint would be pre-
ferred) we believe it represents the best choice of
methodology in the context of this study. We were
concerned about overestimating response to flexion
tests when using the objective system, which was why
subjective lameness scores were used instead, when
evaluating response to treatment. The use of flexion
tests in lameness evaluation is controversial as opin-
ions differ regarding their value. However, the use of
flexion tests is still common practice among racehorse
practitioners and as such, we believe the subjective
grading more accurately reflects real-life practice.
Conclusions
Results from the current study demonstrate that thera-
peutic benefit of ACS may be related to higher levels of
IL-1Ra and IGF-1. Further studies on the association be-
tween the clinical response to intra-articular ACS treat-




The study was designed as a single centre prospective
cohort study, recruiting client-owned harness racehorses
with a suspected low-grade joint related lameness prob-
lem via advertising in a national harness racing maga-
zine. In order to be eligible for inclusion, horses had to
be systemically healthy based on clinical examination,
hematology and serum amyloid A (anti-SAA coated
latex agglutination photometric immunoassay, reference
range 0–20 mg/L) analysis; have no history of receiving
intra-articular treatments during the last 3 months or
pain-relieving medication/treatment within the last 3
days; have detectable lameness which could be abolished
or significantly improved with intra-articular anesthesia
as detailed below; and have no radiographic signs of
moderate to marked OA defined as obvious periarticular
remodeling, joint narrowing, and subchondral bone
sclerosis and/or lysis. Radiographic signs of mild peri-
articular remodeling, defined as small and smoothly
marginated new bone formation, were accepted. Signal-
ment including age, breed and sex were recorded, and a
signed consent form was obtained from owners of all
horses included in the study. Horses were excluded from
follow-up analyses if they received additional treatments
for lameness such as intra-articular medication, extra-
corporeal shockwave therapy or surgical intervention
during the study period.
Clinical examination
A thorough lameness examination including detailed
palpation of the extremities and back was performed in
all horses by two of the authors (PMS and CTF), and ab-
normal findings such as joint effusion or soft tissue ab-
normalities were recorded. Horses were walked and
trotted in hand in a straight line on a hard surface, and
standardized flexion tests (60 s for the proximal fore-
limb, distal fore- and hind limb; and 90 s for the prox-
imal hind limb) were performed. The examiner
performing flexion tests was responsible for attributing a
subjective lameness score (AAEP scale 0–5) for the ini-
tial trot-up and for each of the flexion tests and was
blinded to the result of the objective analysis which was
carried out by another individual (ASK). The objective
analysis consisted of using a wireless inertial sensor-
based lameness evaluation system,1 and the analysis out-
put data (millimetres asymmetry between right and left
limbs) was recorded.
Diagnostic anaesthesia using mepivacaine was per-
formed using aseptic technique in a routine fashion. In
brief, synovial fluid was aspirated to confirm intra-
articular needle placement before injecting a joint-
1Equinosis Lameness Locator
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specific volume of 2% mepivacaine2; 10 ml was used for
carpal joints (radiocarpal and intercarpal joints were
injected simultaneously and hereafter referred to as the
carpus) and for the tarsocrural joint as well as for each
of the stifle compartments; 8 ml was used for metacarpo-
phalangeal and metatarsophalangeal joints; whereas 4 ml
was used for distal interphalangeal joints. Using routine
settings, standard digital radiographic projections were
acquired of all joints responding to intra-articular anal-
gesia. In brief, this included dorso-palmar/plantar; later-
omedial; dorsolateral-palmaro/plantaromedial oblique;
and dorsomedial-palmaro/plantarolateral oblique projec-
tions of the carpus, tarsus and phalangeal joints; flexed
dorsoproximal-dorsodistal projections centered on each
of the proximal and distal row of carpal bones, respect-
ively; and a lateromedial and caudocranial projection of
the stifle.
Horses were re-evaluated (both subjectively and ob-
jectively) after 10 and 30 min. The lameness was consid-
ered localized to a specific joint when the subjective
lameness grading decreased by at least 1 grade (AAEP
score) within 10 min, and when the objective asymmetry
score (in mm) of that limb decreased at least 50% within
the same time frame. When the initial lameness was
abolished or substantially improved by diagnostic anal-
gesia, this joint was referred to as the primary problem.
Secondary problems were identified by continuing the
diagnostic analgesic injections in the same limb in the
event of residual lameness, or in another limb (often
contralateral), when horses shifted their lameness after
the primary problem had been blocked. Horses with
more than two identified painful joints were excluded.
In the event of identifying two localized problems, both
were treated with ACS, however, only data from the pri-
mary problem was used for outcome analyses.
ACS preparation
Upon inclusion in the study, blood was drawn from a
single jugular vein in an aseptic fashion through a 16G
butterfly needle and ACS was prepared using commer-
cially available kits3 and as per the manufacturer’s in-
structions. ACS containers were incubated at 37 °C for
22–24 h, prior to centrifugation (4000 rpm for 10 min)
and serum collection. The resultant ACS was filtered
through a 0.2 μm filter,4 whereupon one aliquot was im-
mediately used for the first joint injection(s). Subsequent
aliquots were stored at − 80 °C for future treatments and
ACS content analyses.
Treatment and re-evaluation
All included horses received a standardized ACS treat-
ment course consisting of 3 intra-articular injections ad-
ministered at approximately 2-week intervals; the exact
treatment intervals and ACS volumes were registered
per case. In general, horses received a total volume of 5
ml ACS per treatment, however, for a few horses the
total extracted ACS volume was less than 15 ml, result-
ing in 2.5–3.5 ml being used per injection. Owners re-
ceived a written standardized exercise programme
recommending 48 h stall rest following each injection.
Briefly, daily walking exercise for 20 min was recom-
mended between the first and second treatment; this
was increased to 30 min between the second and the
third treatment, and further increased to 40 min for 2
weeks after the third injection.
Owners were encouraged to present their horses for
re-evaluation (clinical examination including palpation;
subjective and objective lameness evaluation including
flexion tests) 2 weeks after the third injection; the exact
follow-up time was recorded per case. Adverse effects
were recorded for all treatments and at re-evaluation.
Changes in AAEP scores from inclusion to re-evaluation
were used to categorize clinical outcome; horses were
considered to have responded to treatment when the
subjective AAEP score was 0 on trot-up at re-evaluation,
and when the flexion test scores were at least 50%
reduced.
Cytokine analyses
Equine specific commercially available solid phase sand-
wich ELISA kits5 were used for determining ACS con-
centration of IL-1Ra (DY2466), IL-1β (DY3340), IL-10
(DY1605) and TNFα (DY1814), whereas human-specific
kits were used for TGF-β (DY240) and IGF-1 (DY291),
the latter two having confirmed equine cross-reactivity
[26, 27]. Pre-treatment of ACS samples prior to analysis
for IGF-1 content was performed as described by
Daughaday et al. [28]. For TGF-β content analysis of
ACS, samples were pre-activated using Activation kit 1
(DY010). All standards and samples were assayed in du-
plicates and standard curves were generated for each set
of samples assayed. The reported samples were diluted
1:14 for IGF-1, 1:10 for TGF- β, 1:2 for IL-1Ra, IL-1β
and IL-10 and neat for TNF-α. Twofold dilutions of kit
standards were set up as follows (ng/ml): 20–0,31 for IL-
1Ra and IL-10, 8–0,125 for IL-1β and 2–0,031 for the
remaining analytes. All assays were performed according
to the manufacturer’ instructions and plates were read
using a microplate reader6 set to 450 nm.
2Mepidor vet; Richter Pharma AG, Wels, Austria
3Arthrex ABPS
4Sterifix® 0.2 μm Luer Lock; Braun, Meslungen, Germany
5R&D Systems Europe Ltd.; Abingdon, England, UK
6Multiskan FC Microplate Photometer; Thermo Fisher Scientific,
Massachusetts, US
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Statistical analyses
Spearman’ rho correlation analyses were performed be-
tween the subjective and objective lameness evaluation
methods at inclusion (trot-up, after flexion and after
diagnostic anaesthesia) and at re-evaluation (trot-up and
after flexion). When significantly correlated, the AAEP
scores were used for further analyses. Due to non-
normal distribution of clinical variables, the Wilcoxon’s
rank sum test was used to determine differences be-
tween outcome groups for age; inclusion AAEP scores
for trot-up and flexion; treatment interval in days; days
to follow-up; and the ACS volume used.
Due to positive skewed distributions, the ACS content
of IL-1Ra, IGF-1 and TGF-β were transformed using log
transformation until normal distributions were con-
firmed by the Shapiro-Wilkes test prior to further ana-
lyses. Association between the clinical outcome
(responders vs. non-responders) and age, sex, inclusion
AAEP scores for trot-up and flexion, and the ACS levels
of investigated cytokines and growth factors was deter-
mined using univariable logistic regression analyses. Var-
iables associated with the outcome with a value of P ≤
0.20 were included in a multivariable logistic regression
model; model fit was assessed.
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